Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion-Reference-Cited by-同舟云学术

Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion

Published:2004-04 Issue:1 Volume:50 Page:51-70
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Schagen Frederik H.E.,Ossevoort Martine,Toes Rene E.M.,Hoeben Rob C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference202 articles.

1. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains;Barr;Gene Ther.,1995

2. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a;Engelhardt;Hum. Gene Ther.,1994

3. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver;Engelhardt;Proc. Natl. Acad. Sci. U.S.A.,1994

4. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted;Lusky;J. Virol.,1998

5. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis;Yang;Nat. Genet.,1994

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platelet membrane biomimetic nanoparticle-targeted delivery of TGF-β1 siRNA attenuates renal inflammation and fibrosis;International Journal of Pharmaceutics;2024-06

2. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice;Molecular Therapy;2024-03

3. Protecting Allogeneic Pancreatic Islet Grafts by Engineered Veto;2024-01-07

4. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice;2023-07-12

5. Myocarditis: causes, mechanisms, and evolving therapies;Expert Opinion on Therapeutic Targets;2023-03-04